⌘K

Home/Filings/4/0001209191-19-001575

4//SEC Filing

MORNEAU MICHAEL 4

Accession 0001209191-19-001575

CIK 0001607678other

View on SEC.gov Company Profile

Filed

Jan 2, 7:00 PM ET

Accepted

Jan 3, 8:35 PM ET

Size

5.4 KB

Accession

0001209191-19-001575

Insider Transaction Report

Form 4

Period: 2019-01-03

Viking Therapeutics, Inc.VKTX

MORNEAU MICHAEL

Chief Financial Officer

Transactions

Award
Stock Option (Right to Buy)
2019-01-03+29,000→ 29,000 total
Exercise: $7.58From: 2020-01-03Exp: 2029-01-03→ Common Stock (29,000 underlying)

Footnotes (1)

[F1]25% of the shares subject to the option will vest on each anniversary of the grant date.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Viking Therapeutics, Inc.

CIK 0001607678

Entity typeother

Related Parties

1

filerCIK 0001517780

Filing Metadata

Form type: 4
Filed: Jan 2, 7:00 PM ET
Accepted: Jan 3, 8:35 PM ET
Size: 5.4 KB

View on SEC.gov